Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Early data with the RIPTAC HLD-0915 look competitive.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
